Compare INVH & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INVH | ZBH |
|---|---|---|
| Founded | 2012 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 18.7B |
| IPO Year | 2017 | N/A |
| Metric | INVH | ZBH |
|---|---|---|
| Price | $27.42 | $90.77 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 20 |
| Target Price | $34.90 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 5.3M | 2.1M |
| Earning Date | 10-29-2025 | 02-05-2026 |
| Dividend Yield | ★ 4.37% | 1.06% |
| EPS Growth | ★ 32.35 | N/A |
| EPS | 0.95 | ★ 4.03 |
| Revenue | $2,689,621,000.00 | ★ $8,010,900,000.00 |
| Revenue This Year | $5.69 | $7.98 |
| Revenue Next Year | $3.21 | $5.21 |
| P/E Ratio | $28.89 | ★ $22.51 |
| Revenue Growth | 5.29 | ★ 5.47 |
| 52 Week Low | $26.02 | $85.33 |
| 52 Week High | $35.80 | $114.44 |
| Indicator | INVH | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 44.67 |
| Support Level | $26.72 | $88.50 |
| Resistance Level | $27.43 | $92.82 |
| Average True Range (ATR) | 0.47 | 1.88 |
| MACD | 0.10 | -0.10 |
| Stochastic Oscillator | 93.29 | 38.77 |
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.